Central and peripheral innate and adaptive immunity in Parkinson’s disease
- 8 November 2023
- journal article
- editorial
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (721) , eadk3225
Abstract
Parkinson’s disease (PD) is a multisystem disorder with characteristics of a chronic inflammatory disease. To develop effective immunomodulatory interventions to combat PD, we need to think innovatively about the implications of orchestrated central and peripheral innate and adaptive immune responses that occur as the disease begins and progresses.Keywords
This publication has 52 references indexed in Scilit:
- MHCII Is Required for -Synuclein-Induced Activation of Microglia, CD4 T Cell Proliferation, and Dopaminergic NeurodegenerationThe Journal of Neuroscience, 2013
- Colonic inflammation in Parkinson's diseaseNeurobiology of Disease, 2013
- Is alpha‐synuclein in the colon a biomarker for premotor Parkinson's Disease? Evidence from 3 casesMovement Disorders, 2012
- Increased Intestinal Permeability Correlates with Sigmoid Mucosa alpha-Synuclein Staining and Endotoxin Exposure Markers in Early Parkinson's DiseasePLOS ONE, 2011
- Alpha‐synuclein in colonic submucosa in early untreated Parkinson's diseaseMovement Disorders, 2011
- Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's diseaseNature Genetics, 2010
- Towards the human intestinal microbiota phylogenetic coreEnvironmental Microbiology, 2009
- Parkinson's disease: a dual‐hit hypothesisNeuropathology and Applied Neurobiology, 2007
- Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathologyNeuroscience Letters, 2006
- Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brainsNeurology, 1988